Human Cancer Long Non-Coding RNA Transcriptomes

Gibb, Ewan A.; Vucic, Emily A.; Enfield, Katey S.S.; Stewart, Greg L.; Lonergan, Kim M.; Kennett, Jennifer Y.; Becker‐Santos, Daiana D.; MacAulay, Calum; Lam, Stephen; Brown, Carolyn J.; Lam, Wan L.

doi:10.1371/journal.pone.0025915

Cited by 327 publications

(272 citation statements)

References 72 publications

Supporting

Mentioning

262

Contrasting

Order By: Relevance

“…In addition, other previous studies have reported that ectopic lncRNA expression is associated with tumorigenesis, tumor proliferation, invasion and metastasis (8,30,31). In the present study, differences in the expression levels of lncRNA RP11-119F7.4 were observed between the gastric cancer tissues and matched NATs.…”

Section: A B Discussionsupporting

confidence: 60%

Novel long non-coding RNA RP11-119F7.4 as a potential biomarker for the development and progression of gastric cancer

et al. 2015

View full text Add to dashboard Cite

Abstract. Long non-coding RNAs (lncRNAs) have been reported to be involved in gene dysregulation in numerous different types of cancer, and have subsequently emerged as a major series of regulatory molecules that participate in a broad range of biological and pathological processes. However, the correlation between the expression levels of lncRNAs and their clinical significance in gastric cancer remains unclear. The aim of the present study was to investigate the potential correlation between lncRNA RP11-119F7.4 expression and clinicopathological characteristics in gastric cancer, and to identify whether it can serve as a potential diagnostic biomarker of the disease. Total RNA was extracted from the tissues of 96 patients with gastric cancer, in addition to matched non-tumor adjacent tissues (NATs). Following reverse transcription, lncRNA RP11-119F7.4 expression levels were determined by quantitative polymerase chain reaction and the association with patient clinicopathological characteristics was further analyzed. A receiver operating characteristic (ROC) curve was constructed to determine the diagnostic value of RP11-119F7.4. The results demonstrated that RP11-119F7.4 expression was significantly downregulated in the gastric cancer tissues compared with the matched NATs (P<0.001) and was significantly associated with the macroscopic type (P=0.041) and Lauren grade (P=0.020). The area under the ROC curve was 0.637 (P<0.001). However, no statistically significant differences were observed between RP11-119F7.4 expression and patient survival. The results of the present study indicate that lncRNA RP11-119F7.4 may be involved in carcinogenesis and may prove useful as a biomarker for diagnosis and prognostic significance in patients with gastric cancer.

show abstract

Section: A B Discussionsupporting

confidence: 60%

Novel long non-coding RNA RP11-119F7.4 as a potential biomarker for the development and progression of gastric cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Furthermore, NEAT1 expression was associated with oncogenic activity and metastatic progression in lung cancer (35,36). However, downregulation of NEAT1 has been observed in the several other malignancies, including those affecting the liver, retina and esophagus (37). Furthermore, anomalous NEAT1 expression has been reported in various human malignancies, including acute promyelocytic leukemia, where NEAT1 repression was predominant in patients with leukemia caused by promyelocytic leukemia-retinoic acid receptor α (RARα) gene translocation (17).…”

Section: Discussionmentioning

confidence: 99%

Overexpression of lncRNA NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemia

et al. 2016

View full text Add to dashboard Cite

Abstract. Leukemia is a heterogeneous clonal disorder in which early hematopoietic cells fail to differentiate and do not undergo programmed cell death or apoptosis. Less than one-third of adult patients with leukemia are managed using current therapies due to the emergence of multidrug resistance (MDR), emphasizing the need for newer and more robust approaches. Recent reports have suggested that long non-coding RNAs (lncRNAs) contribute to selective gene expression and, hence, could be manipulated effectively to halt the progression of cancer. However, little is known regarding the role of lncRNA in leukemia. Nuclear paraspeckle assembly transcript 1 (NEAT1) is a nuclear-restricted lncRNA involved in the pathogenesis of certain types of cancer. Deregulated expression of NEAT1 has been reported in a number of human malignancies, including leukemia and other solid tumors. The present study aimed to characterize the role of NEAT1 in the regulation of MDR in leukemia. Using reverse transcription-quantitative polymerase chain reaction, it was demonstrated that NEAT1 messenger RNA (mRNA) expression levels were significantly downregulated in leukemia patient samples compared with those from healthy donors. Furthermore, NEAT1 mRNA expression was repressed in a number of leukemia cell lines, including K562, THP-1, HL-60 and Jurkat cells, compared with peripheral white blood control cells, consistent with the expression observed in patients with leukemia. In addition, the transfection of a NEAT1 overexpression plasmid into K562 and THP-1 leukemia cell lines alleviated MDR induced by cytotoxic agents, such as Alisertib and Bortezomib, through inhibition of ATP-binding cassette G2. Although more robust studies are warranted, the current findings provide the basis for the use of NEAT1 as a novel promising target in the treatment of leukemia.

show abstract

“…They are crucial for normal tissue maintenance and function, and they are aberrantly expressed in several cancer subtypes. [62][63][64] Several lncRNAs are essential for maintaining the pluripotent state by being downstream targets of the Oct4 and Nanog transcription factors, while others are necessary for repressing linage-specific gene expression and are enriched for EZH2 and SUZ12 subunits in mouse ESCs. 65,66 LncRNAs may themselves be epigenetically regulated through EZH2-driven H3K27 promoter methylation, proposing a transcription regulation mechanism of lncRNAs.…”

Section: Lncrnas Biologymentioning

confidence: 99%

Non‐coding RNAs and EZH2 interactions in cancer: Long and short tales from the transcriptome

Benetatos¹,

Voulgaris

Vartholomatos

et al. 2012

Intl Journal of Cancer

View full text Add to dashboard Cite

A large amount of data indicates that non‐coding RNAs represent more than the “dark matter” of the genome. Both microRNAs and long non‐coding RNAs are involved in several fundamental biologic processes, and their deregulation may lead in oncogenesis. Interacting with the Polycomb‐repressive complex 2 subunit EZH2, they could affect the expression of protein‐coding genes and form feedback networks and autoregulatory loops. They can also form networks with upstream and downstream important factors, in which EZH2 represent the stabilizing factor of the pathway. As such non‐coding RNAs affect the epigenetic modifications leading to malignant transformation.

show abstract

Human Cancer Long Non-Coding RNA Transcriptomes

Cited by 327 publications

References 72 publications

Novel long non-coding RNA RP11-119F7.4 as a potential biomarker for the development and progression of gastric cancer

Novel long non-coding RNA RP11-119F7.4 as a potential biomarker for the development and progression of gastric cancer

Overexpression of lncRNA NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemia

Non‐coding RNAs and EZH2 interactions in cancer: Long and short tales from the transcriptome

Contact Info

Product

Resources

About